Protagonist Therapeutics Revenue 2015-2021 | PTGX

Protagonist Therapeutics revenue from 2015 to 2021. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
Protagonist Therapeutics Annual Revenue
(Millions of US $)
2020 $29
2019 $0
2018 $31
2017 $20
2016 $
2015 $
2014 $
Protagonist Therapeutics Quarterly Revenue
(Millions of US $)
2021-06-30 $2
2021-03-31 $6
2020-12-31 $6
2020-09-30 $13
2020-06-30 $6
2020-03-31 $4
2019-12-31 $3
2019-09-30 $4
2019-06-30 $-8
2019-03-31 $2
2018-12-31 $2
2018-09-30 $6
2018-06-30 $12
2018-03-31 $11
2017-12-31 $11
2017-09-30 $9
2017-06-30
2017-03-31
2016-12-31
2016-09-30
2016-06-30
2016-03-31
2015-12-31
2015-09-30
2015-06-30
2014-12-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.894B $0.029B
Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company with a proprietary technology platform focused on discovering and developing peptide-based new chemical entities to address significant unmet medical needs. The Company's initial lead product candidates consists of PTG-100 and PTG-200, which have the potential to transform the existing treatment paradigm for inflammatory bowel disease, a GI disease consisting primarily of ulcerative colitis and Crohn's disease; PTG-300, an injectable hepcidin mimetic. Protagonist Therapeutics, Inc. is based in Milpitas, United States.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $133.838B 8.91
Bio-Rad Laboratories (BIO.B) United States $23.483B 50.05
QIAGEN (QGEN) Netherlands $12.341B 20.90
Biohaven Pharmaceutical Holding (BHVN) United States $8.723B 0.00
Emergent Biosolutions (EBS) United States $2.813B 6.79
Arcus Biosciences (RCUS) United States $2.568B 0.00
Myovant Sciences (MYOV) United Kingdom $2.170B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.949B 0.00
Zymeworks (ZYME) Canada $1.323B 0.00
Ambrx Biopharma (AMAM) United States $0.509B 0.00
SQZ Biotechnologies (SQZ) United States $0.428B 0.00
Enzo Biochem (ENZ) United States $0.174B 51.29